BioCryst Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, ORLADEYO net revenue expected to be between $380-$400 million in 2024, on trajectory for $1 billion in peak sales. The Company expects operating profit in 2024, approaching positive EPS.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.32 USD | -0.37% | +19.55% | -11.19% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.19% | 1.1B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- BCRX Stock
- News BioCryst Pharmaceuticals, Inc.
- BioCryst Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024